The Hackensack Meridian John Theurer Cancer Center (JTCC), New Jersey’s top-ranked cancer center and a leading research partner of the NCI-designated Lombardi Comprehensive Cancer Center, is set to present one of its largest and most diverse scientific contributions to date at the 67th American Society of Hematology (ASH) Annual Meeting. JTCC investigators will present a remarkable 65 studies at the conference in Orlando, taking place December 6–9, 2025.
The breadth of the research highlights major innovations across nearly every hematologic disease area, including breakthroughs in:
-
Advanced Cell Therapy (CAR-T Science)
-
Targeted Agents and Immunotherapies
-
AI-Driven Diagnostics and Prediction
-
Stem Cell Transplantation (HCT)
-
Real-World Evidence (RWE)
Shaping the Future of Blood Cancer Care
Dr. André Goy, chair, physician-in-chief, and vice president of oncology at Hackensack Meridian Health, emphasized the center’s mission: “John Theurer Cancer Center continues to help shape the future of blood cancer care. Our teams are redefining transplantation, advancing CAR-T science, and co-leading trials testing next-generation targeted therapies and immunotherapies.”
He noted that the sheer depth and breadth of the ASH presentations underscore the center’s commitment “to bring transformational science rapidly to the clinic for patients with blood cancers and other serious blood disorders.”
The 65 abstracts cover cutting-edge work in major blood cancers and noncancerous blood disorders:
Leukemias
Investigators will present updated results on several key trials, including the Phase 2 dose confirmation trial of oral ASTX030 for myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Additionally, a Phase 1 study provided updated safety and clinical activity results for Ziftomenib in combination with venetoclax and azacitidine for relapsed/refractory AML. A major focus is also on AI, with a study on AI-derived prediction of response and relapse to venetoclax-based therapy in AML.
Lymphoma
The center is presenting long-term data on novel therapies, including three-year outcomes for Epcoritamab in combination with R-mini-CHOP for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and the promising results of Epcoritamab with rituximab and lenalidomide for previously untreated follicular lymphoma (FL). Other studies focus on the use of Brexucabtagene autoleucel (brexu-cel) in relapsed/refractory Mantle Cell Lymphoma (MCL) and Burkitt lymphoma (BL).
Multiple Myeloma
JTCC’s work in Multiple Myeloma features extensive real-world evidence on next-generation therapies. Studies include real-world outcomes with the bispecific antibody Elranatamab and updated safety and efficacy results for Talquetamab. Furthermore, research on Ciltacabtagene autoleucel (cilta-cel) focuses on identifying modifiable risk factors associated with delayed neurotoxicity.
Technology and Noncancerous Disorders
Beyond cancer, the center’s presentations include research on noncancerous conditions like Sickle Cell Disease (SCD), showcasing results from the BMT CTN 1507 trial on reduced intensity bone marrow transplantation and a study on base editing for robust HbF induction. Technological innovations include the use of AI to analyze the bone marrow microenvironment in Myelodysplastic Syndrome and studies on B- and T-cell clonality using peripheral blood cell-free RNA in liquid biopsy.
